New combo therapy aims to extend life for elderly esophageal cancer patients
NCT ID NCT07196345
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a chemotherapy drug (TAS-102) combined with radiation in people aged 65-85 with advanced esophageal cancer. The goal is to find the safest dose and see if the combination helps control the cancer and improves survival. About 45 participants will take part across multiple hospitals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Shandong First Medical University
Jinan, Shandong, 250000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a video call replace a clinic visit for cancer patients on radiotherapy?
- Two-Drug cocktail aims to shrink Hard-to-Treat esophageal and stomach tumors
- Breast reconstruction after mastectomy: which approach leads to happier patients?
- Two-Drug combo aims to wipe out rectal cancer before surgery
- Immunotherapy combo may boost rectal cancer treatment
- Gut radiation may revive immunotherapy in resistant cancers